FI981954A - Parannettu näkökyky silmän fotodynaamisen terapian avulla - Google Patents

Parannettu näkökyky silmän fotodynaamisen terapian avulla Download PDF

Info

Publication number
FI981954A
FI981954A FI981954A FI981954A FI981954A FI 981954 A FI981954 A FI 981954A FI 981954 A FI981954 A FI 981954A FI 981954 A FI981954 A FI 981954A FI 981954 A FI981954 A FI 981954A
Authority
FI
Finland
Prior art keywords
eye
photodynamic therapy
improved vision
vision
improved
Prior art date
Application number
FI981954A
Other languages
English (en)
Swedish (sv)
Other versions
FI981954A0 (fi
Inventor
H Andrew Strong
Julia Levy
Gustav Huber
Mario Fsadni
Original Assignee
Qlt Phototherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qlt Phototherapeutics Inc filed Critical Qlt Phototherapeutics Inc
Publication of FI981954A0 publication Critical patent/FI981954A0/fi
Publication of FI981954A publication Critical patent/FI981954A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
FI981954A 1996-03-11 1998-09-11 Parannettu näkökyky silmän fotodynaamisen terapian avulla FI981954A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/613,420 US5756541A (en) 1996-03-11 1996-03-11 Vision through photodynamic therapy of the eye
PCT/CA1997/000134 WO1997033619A1 (en) 1996-03-11 1997-02-25 Improved vision through photodynamic therapy of the eye

Publications (2)

Publication Number Publication Date
FI981954A0 FI981954A0 (fi) 1998-09-11
FI981954A true FI981954A (fi) 1998-11-10

Family

ID=24457246

Family Applications (1)

Application Number Title Priority Date Filing Date
FI981954A FI981954A (fi) 1996-03-11 1998-09-11 Parannettu näkökyky silmän fotodynaamisen terapian avulla

Country Status (22)

Country Link
US (6) US5756541A (fi)
EP (1) EP0894009B1 (fi)
JP (2) JP2000506173A (fi)
KR (1) KR100433507B1 (fi)
CN (1) CN1104908C (fi)
AR (2) AR004422A1 (fi)
AT (1) ATE301473T1 (fi)
CA (1) CA2248087C (fi)
CZ (1) CZ299301B6 (fi)
DE (1) DE69733943T2 (fi)
DK (1) DK0894009T3 (fi)
ES (1) ES2246505T3 (fi)
FI (1) FI981954A (fi)
HK (1) HK1018203A1 (fi)
HU (1) HU227978B1 (fi)
IL (4) IL126099A (fi)
NO (1) NO984163L (fi)
NZ (1) NZ331736A (fi)
PL (1) PL188888B1 (fi)
TW (1) TW448045B (fi)
WO (1) WO1997033619A1 (fi)
ZA (1) ZA971820B (fi)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265039A (zh) * 1996-12-11 2000-08-30 环状药物公司 泰克萨菲瑞在制备用于诊断和治疗眼部疾病的药物中的应用
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
AU734366B2 (en) * 1997-02-11 2001-06-14 Novartis Ag Compositions and articles for reducing the effects of inflammation
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
US7022843B1 (en) 1999-04-14 2006-04-04 The University Of British Columbia β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US6443976B1 (en) * 1999-11-30 2002-09-03 Akorn, Inc. Methods for treating conditions and illnesses associated with abnormal vasculature
US7078014B2 (en) * 1999-12-23 2006-07-18 Health Research, Inc. Method for using chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US6534040B2 (en) 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
US7097826B2 (en) 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
CA2395567A1 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
AU2001234979B2 (en) 2000-02-10 2006-07-27 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
AU2001250401B2 (en) * 2000-03-24 2005-08-11 Novartis Ag Improved treatment of neovascularization
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
US7753943B2 (en) * 2001-02-06 2010-07-13 Qlt Inc. Reduced fluence rate PDT
WO2002062384A2 (en) * 2001-02-06 2002-08-15 Qlt Inc. Reduced fluence rate pdt
US8106038B2 (en) 2001-02-15 2012-01-31 Qlt Inc. Method for reducing or preventing PDT related inflammation
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
TWI260327B (en) * 2001-11-09 2006-08-21 Osi Eyetech Inc Pharmaceutical compositions for treating ocular neovascular diseases
US20030167033A1 (en) * 2002-01-23 2003-09-04 James Chen Systems and methods for photodynamic therapy
DK1485007T3 (da) * 2002-03-20 2008-02-04 Novadaq Technologies Inc System og fremgangsmåde til visualisering af væskeströmning gennem kar
CN1678342A (zh) * 2002-07-02 2005-10-05 加州大学评议会 眼病症治疗
ATE535219T1 (de) * 2002-07-17 2011-12-15 Novadaq Technologies Inc Kombinierte photokoagulations- und photodynamische therapie
EP1549268A2 (en) * 2002-10-03 2005-07-06 Light Sciences Corporation Excitation of photoreactive compounds in eye tissue
WO2004034889A2 (en) * 2002-10-18 2004-04-29 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization
WO2004073492A2 (en) * 2003-02-14 2004-09-02 Massachusetts Eye And Ear Infirmary Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof
ATE442861T1 (de) * 2003-03-07 2009-10-15 Univ Texas Gegen antikörper gerichtete photodynamische therapie
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
CA2525447C (en) * 2003-05-14 2013-08-06 Universite De Sherbrooke Amphiphilic trisulfonated porphyrazines for photodynamic applications in medicine
CN100534428C (zh) * 2003-08-25 2009-09-02 上海复旦张江生物医药股份有限公司 血卟啉单甲醚在治疗眼科疾病中的应用
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
CN1980651A (zh) * 2004-05-07 2007-06-13 加州大学评议会 近视的治疗
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
JP2008510529A (ja) * 2004-08-27 2008-04-10 エレックス メディカル プロプライエタリー リミテッド 選択的眼科レーザ治療
TW200610555A (en) * 2004-09-24 2006-04-01 Light Sciences Corp Extended treatment of tumors through vessel occlusion with light activated drugs
ZA200704872B (en) * 2004-11-17 2008-12-31 Mclaurin Joanne Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation
JP2008524224A (ja) * 2004-12-15 2008-07-10 ライト サイエンシズ オンコロジー、インコーポレイテッド 閉塞作用を強化した光線力学的療法
WO2006091666A2 (en) * 2005-02-23 2006-08-31 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US20070122344A1 (en) 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
EP1940373B8 (en) * 2005-10-13 2015-06-24 Waratah Pharmaceuticals, Inc. 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
WO2007097839A2 (en) * 2006-02-16 2007-08-30 Massachusetts Eye And Ear Infirmary Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
US20070197453A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
US20100113613A1 (en) * 2006-03-09 2010-05-06 Waratah Pharmaceuticals cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
CA2652449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
WO2008034244A1 (en) * 2006-09-21 2008-03-27 Waratah Pharmaceuticals Inc. The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases
JP2010507412A (ja) 2006-10-25 2010-03-11 エレックス アールアンドディー プロプライエタリー リミテッド 網膜再生
CA2670405A1 (en) * 2006-11-24 2008-05-29 Waratah Pharmaceuticals Inc. Combination treatments for alzheimer's disease and related neurodegenerative diseases
WO2008103299A2 (en) 2007-02-16 2008-08-28 Massachusetts Eye & Ear Infirmary Methods and compositions for prognosing, detecting, and treating age-related macular degeneration
US20100331267A1 (en) * 2007-04-12 2010-12-30 Mclaurin Joanne Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
CA2683548A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
EP2656839A1 (en) 2007-04-12 2013-10-30 Waratah Pharmaceuticals, Inc. Use of Cyclohexanehexol Derivatives in the Treatment of Ocular Diseases
CA2683580A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
US8496649B2 (en) * 2007-05-30 2013-07-30 Ellex R&D Pty Ltd Retinal rejuvenation laser
WO2009061830A1 (en) * 2007-11-06 2009-05-14 Massachusetts Eye & Ear Infirmary Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
WO2009126894A2 (en) * 2008-04-11 2009-10-15 Massachusetts Eye And Ear Infirmary Methods and compositions for the diagnosis and treatment of angiogenic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
EP2687235A3 (en) 2008-05-02 2014-11-05 Novadaq Technologies Inc. Methods for production and use of substance-loaded erythrocytes (S-LES) for observation and treatment of microvascular hemodynamics
JP2012505162A (ja) * 2008-10-09 2012-03-01 ワラタ ファーマシューティカルズ， インコーポレイテッド 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用
KR101018785B1 (ko) * 2008-11-28 2011-03-03 삼성전기주식회사 전자기 밴드갭 구조물 및 회로 기판
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
US20140004510A1 (en) 2010-09-24 2014-01-02 Massachusetts Eye And Ear Infirmary Methods and compositions for prognosing and/or detecting age-related macular degeneration
WO2013027222A1 (en) * 2011-08-23 2013-02-28 Yeda Research And Development Co.Ltd. (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders
US9211214B2 (en) 2012-03-21 2015-12-15 Valeant Pharmaceuticals International, Inc Photodynamic therapy laser
EP2863801B8 (en) 2012-06-21 2024-06-12 Stryker Corporation Quantification and analysis of angiography and perfusion
US9962251B2 (en) 2013-10-17 2018-05-08 Boston Scientific Scimed, Inc. Devices and methods for delivering implants
JP6549705B2 (ja) 2014-09-29 2019-07-24 ノバダック テクノロジーズ ユーエルシー 自己蛍光の存在下での、生物的物質内のターゲット蛍光体のイメージング
JP6487544B2 (ja) 2014-10-09 2019-03-20 ノバダック テクノロジーズ ユーエルシー 蛍光媒介光電式容積脈波記録法を用いた組織中の絶対血流の定量化
CN106620893B (zh) 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
EP3970720B1 (en) 2016-05-26 2023-07-05 University of Pittsburgh- Of the Commonwealth System of Higher Education Compositions and methods for treating pulmonary vascular disease
US11140305B2 (en) 2017-02-10 2021-10-05 Stryker European Operations Limited Open-field handheld fluorescence imaging systems and methods
KR20190056758A (ko) 2017-11-17 2019-05-27 주식회사 지뉴브 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179120A (en) 1991-06-28 1993-01-12 Cytopharm, Inc. Porphycene compounds for photodynamic therapy
US5776966A (en) 1992-05-27 1998-07-07 University Of British Columbia Selective cell inactivation in blood
WO1995024930A1 (en) * 1994-03-14 1995-09-21 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
JP2961074B2 (ja) 1995-09-06 1999-10-12 明治製菓株式会社 光化学療法用の新生血管閉塞剤

Also Published As

Publication number Publication date
US20080058403A1 (en) 2008-03-06
ES2246505T3 (es) 2006-02-16
AR004422A1 (es) 1998-12-16
HUP9902012A3 (en) 2000-04-28
EP0894009B1 (en) 2005-08-10
IL220143A0 (en) 2012-07-31
US20030149012A1 (en) 2003-08-07
ATE301473T1 (de) 2005-08-15
HU227978B1 (en) 2012-07-30
NO984163D0 (no) 1998-09-10
PL328796A1 (en) 1999-02-15
DE69733943T2 (de) 2006-06-01
WO1997033619A1 (en) 1997-09-18
IL220210A0 (en) 2012-07-31
JP2000506173A (ja) 2000-05-23
KR100433507B1 (ko) 2004-12-23
DK0894009T3 (da) 2005-10-31
JP2006273853A (ja) 2006-10-12
NZ331736A (en) 2000-06-23
AU705100B2 (en) 1999-05-13
AU1762697A (en) 1997-10-01
CN1104908C (zh) 2003-04-09
CA2248087C (en) 2007-10-16
PL188888B1 (pl) 2005-05-31
HK1018203A1 (en) 1999-12-17
IL126099A (en) 2012-08-30
IL126099A0 (en) 1999-05-09
HUP9902012A2 (hu) 1999-12-28
US5910510A (en) 1999-06-08
US6548542B1 (en) 2003-04-15
AR042931A2 (es) 2005-07-06
US8239978B2 (en) 2012-08-14
FI981954A0 (fi) 1998-09-11
TW448045B (en) 2001-08-01
ZA971820B (en) 1997-10-10
IL187758A0 (en) 2008-03-20
CA2248087A1 (en) 1997-09-18
US20120310144A1 (en) 2012-12-06
DE69733943D1 (de) 2005-09-15
KR19990087682A (ko) 1999-12-27
CN1213314A (zh) 1999-04-07
CZ299301B6 (cs) 2008-06-11
CZ278998A3 (cs) 1999-05-12
US5756541A (en) 1998-05-26
EP0894009A1 (en) 1999-02-03
NO984163L (no) 1998-11-11

Similar Documents

Publication Publication Date Title
FI981954A (fi) Parannettu näkökyky silmän fotodynaamisen terapian avulla
CA2155833A1 (en) Photodynamic treatment of synovium
AU1302699A (en) Photodynamic therapy method and apparatus
AR037307A1 (es) Metodos para el tratamiento de enfermedades oculares neovasculares
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
EP0726083A3 (en) Method and apparatus for the diagnostic and composite pulsed heating and photodynamic therapy treatment
WO2002069825A3 (en) Apparatus and method for photocosmetic and photodermatological treatment
HU9303320D0 (en) Method for developing sight lens and sight repairing lens
WO2007146101A3 (en) Continuous low irradiance photodynamic therapy system and method
WO2002038078A3 (en) A method and apparatus for the correction of presbyopia using high intensity focused ultrasound
AR021061A1 (es) Metodo para producir imagenes y terapia fotodinamica mejoradas
NZ336196A (en) Use of green porphyrins for the treatment of secondary cataracts
AU732673C (en) Device for the photodynamic treatment of living beings and of the organs thereof
AU1403399A (en) Method of treatment of pigmented cancer cells utilizing photodynamic therapy
NO881051D0 (no) Metoder for behandling av solskadet, human hud med retinoider.
CA2112444A1 (en) Medical Laser Apparatus and Diagnosing/Curing Apparatus Using the Medical Laser Apparatus
WO2002053224A3 (fr) Procede et dispositif de photo-surveillance complexe du poids corporel
JPH04338474A (ja) 医療用レーザ装置
WO2005105211A3 (en) Fractionized light pdt therapy for posterior eye disease
RU96121849A (ru) Способ лечения амблиопии
RU97116656A (ru) Способ лечения цистита
RU97113539A (ru) Способ лечения заболеваний, вызываемых микроорганизмами
DK0831909T3 (da) Anvendelse af en precursor af protoporphyrin IX i behandlingen af dermatofytoser og malaria efter fotoaktivering af protoporphyrinet
CO4340602A1 (es) Estructura perfeccionada para gafas protectoras
UA32205A (uk) Спосіб лікування хворих з інфікованим вогнищем